At BridgeBio we focus on developing genetic disease products to help patients with grievous diseases. Our core values of Put Patients First, Let Science Speak, Think Independently, Be Radically Transparent, and Every Minute Counts guide us through everything we do. BridgeBio is looking for an administrative assistant to the CEO, Dr. Neil Kumar in our Palo Alto office. We are seeking someone to join our Executive Assistant team who is interested in learning and growing as BridgeBio grows. What we offer: Patient Days, where we are fortunate enough to learn more about the lives we are looking... view job details
Calcilytix Therapeutics, a subsidiary of BridgeBio Pharma, is a clinical stage biopharmaceutical company focused on addressing disorders of calcium homeostasis at the source. Our product candidate is an orally-administered small molecule that specifically inhibits the calcium sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium. BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for p... view job details
About Calcilytix, Cantero & BridgeBio Pharma Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is developing CLTX-305 (encaleret), a negative allosteric modulator of the calcium-sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (a genetic cause of hypoparathyroidism due to gain-of-function mutations in CaSR). Encaleret is currently being evaluated in a Phase 2 clinical study and has received Orphan Drug and Fast Track Designations from the US FDA. Cantero Therapeutics, formerly known as Orfan Biotech, is an affiliate of BridgeBio Pharma founded in 2... view job details
CoA Therapeutics, a BridgeBio Pharma company, is a clinical-stage biopharmaceutical company developing novel therapies for difficult to treat and rare genetic disorders by harnessing advances in understanding the CoA pathway. CoA’s team of veteran biotechnology executives are partnering with patients and physicians to bring forth effective therapies for PKAN, organic acidemias, and other diseases as quickly as possible. BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial ... view job details
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs. Founded in 2015 by a team of industry veterans, the company has built a portfolio of 20 transformative drugs ranging from pre-clinical to late-stage development in multiple therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. The company’s focus on scientific ex... view job details
Navire Pharma, a subsidiary of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on harnessing breakthrough discoveries in our understanding of SHP2 to address the large and growing unmet need in rare and difficult-to-treat cancers. Navire’s team of veteran biotechnology executives are partnering with leading cancer experts to advance effective therapies to patients as rapidly as possible. BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine requ... view job details
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs. Founded in 2015 by a team of industry veterans, the company has built a portfolio of 20 transformative drugs ranging from pre-clinical to late-stage development in multiple therapeutic areas including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. The company’s focus on scientific exc... view job details
BridgeBio ultimately exists to help patients. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between the business case and scientific possibility, between patient and hope. To learn more, visit us at https://bridgebio.com Who You Are: BridgeBio is dedicated to finding and developing targeted therapies for the betterment of patients with genetic disease. We view our academic collaborations and net... view job details
With a singular focus, QED, s subsidiary of BridgeBio Pharma, is devoted to the development of our investigational candidate, infigratinib. A first-in-class, selective, tyrosine kinase inhibitor, infigratinib has promising early clinical data in patients with previously treated, FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as preclinical studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders. FGFR=fibroblast growth factor receptor. BridgeBio finds, develops, and delivers breakthrough med... view job details
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs. Founded in 2015 by a team of industry veterans, the company has built a portfolio of 20 transformative drugs ranging from pre-clinical to late-stage development in multiple therapeutic areas including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. The company’s focus on scientific exc... view job details